A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

Intellia Therapeutics faces a pivotal moment as the biotech firm prepares to release third-quarter financial results. While the company is scheduled to present Q3 figures on Thursday, investor ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Caribou Biosciences said its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

This growth is fueled by the escalating demand for biologics and biosimilars, continued innovation in cell line engineering, and increasing applications in gene therapy, monoclonal antibody production ...

Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...